ATRS Key Statistics, Chart & Performance
The current stock price of ATRS is 5.59 null. In the past month the price increased by 0.54%. In the past year, price increased by 40.81%.
ATRS Latest News, Press Relases and Analysis
ATRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.28 | 982.81B | ||
| JNJ | JOHNSON & JOHNSON | 19.85 | 496.32B | ||
| MRK | MERCK & CO. INC. | 11.59 | 253.41B | ||
| PFE | PFIZER INC | 7.98 | 145.24B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.65 | 102.22B | ||
| ZTS | ZOETIS INC | 19.66 | 54.92B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.63 | 22.85B | ||
| VTRS | VIATRIS INC | 4.66 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.35 | 11.14B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.68 | 8.76B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.43B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.34B |
Related stock screener links
About ATRS
Company Profile
Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. The company is headquartered in Ewing, New Jersey and currently employs 201 full-time employees. The firm is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The firm develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The firm products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.
Company Info
ANTARES PHARMA INC
100 Princeton South, Suite 300
Ewing NEW JERSEY 08628 US
CEO: Robert F. Apple
Employees: 201
Phone: 16093593020.0
ANTARES PHARMA INC / ATRS FAQ
Can you describe the business of ANTARES PHARMA INC?
Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. The company is headquartered in Ewing, New Jersey and currently employs 201 full-time employees. The firm is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The firm develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The firm products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.
Can you provide the latest stock price for ANTARES PHARMA INC?
The current stock price of ATRS is 5.59 null.
Does ANTARES PHARMA INC pay dividends?
ATRS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATRS stock?
ATRS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the employee count for ATRS stock?
ANTARES PHARMA INC (ATRS) currently has 201 employees.
What is the market capitalization of ATRS stock?
ANTARES PHARMA INC (ATRS) has a market capitalization of 955.06M null. This makes ATRS a Small Cap stock.
ATRS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ATRS. When comparing the yearly performance of all stocks, ATRS is one of the better performing stocks in the market, outperforming 98.01% of all stocks.
ATRS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ATRS. ATRS has only an average score on both its financial health and profitability.
ATRS Financial Highlights
Over the last trailing twelve months ATRS reported a non-GAAP Earnings per Share(EPS) of 0.27. The EPS increased by 350% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.15% | ||
| ROA | 17.97% | ||
| ROE | 26.33% | ||
| Debt/Equity | 0.1 |
ATRS Forecast & Estimates
12 analysts have analysed ATRS and the average price target is 6.07 null. This implies a price increase of 8.57% is expected in the next year compared to the current price of 5.59.
For the next year, analysts expect an EPS growth of -69.78% and a revenue growth 15.42% for ATRS